Affiliation:
1. Division of Gastroenterology and Hepatology, Mayo Clinic , Rochester, Minnesota , USA
Abstract
Lay Summary
Upadacitinib, a selective JAK-1 inhibitor, was used as rescue therapy for ulcerative colitis in the setting of pregnancy following use of mesalamine, vedolizumab, infliximab, and corticosteroids. This resulted in an uncomplicated live full birth without need for surgical intervention.
Publisher
Oxford University Press (OUP)